Take orally, preferably 15-30 minutes before meals. Do not crush or chew the tablet; swallow whole with water.

Domperidone is a peripheral dopamine D2 receptor antagonist that primarily acts at the chemoreceptor trigger zone (CTZ) in the brain and in the gastrointestinal tract. By blocking dopamine receptors, it increases lower esophageal sphincter tone, improves gastroduodenal motility and peristalsis, and prevents reflux, leading to antiemetic and prokinetic effects.

• •Hypersensitivity to domperidone or any excipients
• •Prolactin-releasing pituitary tumour (prolactinoma)
• •Moderate to severe hepatic impairment
• •Conditions where stimulation of gastric motility could be harmful (e.g., gastrointestinal haemorrhage, mechanical obstruction, perforation)
• •Concomitant use of strong CYP3A4 inhibitors (e.g., ketoconazole, erythromycin)

Store below 30°C in a dry place, away from light and moisture. Keep out of reach of children.

Symptoms include drowsiness, disorientation, extrapyramidal reactions (especially in children), and cardiac arrhythmias. Treatment is symptomatic and supportive, including gastric lavage and activated charcoal. ECG monitoring is recommended due to the risk of QT prolongation.

Pregnancy: Use with caution during pregnancy only if clearly needed and the potential benefits outweigh the potential risks to the fetus. Limited human data suggest no increased risk of major congenital malformations. Lactation: Domperidone is excreted in breast milk in small amounts. Monitor breastfed infants for potential cardiac effects. Consult a doctor.